ImmuPharma PLC: Encouraging Final Phase IIb Results Seen With LUPUZOR™ In Systemic Lupus Erythematosus

ImmuPharma PLC (LSE:IMM) the specialist discovery and development pharmaceutical company is pleased to announce the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care. The study results also show that Lupuzor™ was generally well tolerated, with adverse event rates lower with Lupuzor™ when compared to placebo.